tradingkey.logo
搜尋

Valneva SE

VALN
添加自選
5.680USD
-0.260-4.38%
收盤 05/15, 16:00美東報價延遲15分鐘
545.56M總市值
虧損本益比TTM

Valneva SE

5.680
-0.260-4.38%

關於 Valneva SE 公司

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SE簡介

公司代碼VALN
公司名稱Valneva SE
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
員工數量- -
證券類型Depository Receipt
年結日Jun 28
公司地址6, Rue Alain Bombard
城市SAINT-HERBLAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編44800
電話33228073710
網址https://valneva.com/
公司代碼VALN
上市日期Jun 28, 2007
CEOLingelbach (Thomas)

Valneva SE公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--

收入明細

單位: USD更新時間: 4月6日 週一
單位: USD更新時間: 4月6日 週一
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
其他
6.77M
3.87%
地區USD
名稱
營收
佔比
United States
53.61M
30.69%
Canada
30.13M
17.25%
Germany
17.47M
10.00%
France
14.67M
8.40%
Nordics
13.90M
7.96%
其他
44.89M
25.70%
業務
地區
業務USD
名稱
營收
佔比
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
其他
6.77M
3.87%

股東統計

更新時間: 5月7日 週四
更新時間: 5月7日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
其他
94.66%
持股股東
持股股東
佔比
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
其他
94.66%
股東類型
持股股東
佔比
Venture Capital
2.44%
Private Equity
2.42%
Investment Advisor
0.43%
Research Firm
0.17%
Hedge Fund
0.02%
其他
94.51%

機構持股

更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
36
5.21M
5.50%
-309.16K
2025Q4
32
5.27M
6.14%
+505.55K
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Novo Holdings A/S
2.31M
2.66%
-40.00K
-1.71%
Dec 31, 2025
Frazier Life Sciences Management, L.P.
2.29M
2.64%
--
--
Dec 31, 2025
General American Investors Company, Inc.
354.36K
0.41%
--
--
Dec 31, 2025
Wells Fargo Advisors
123.46K
0.14%
-30.53K
-19.82%
Dec 31, 2025
Morgan Stanley & Co. International Plc
32.26K
0.04%
+9.49K
+41.70%
Dec 31, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
--
--
Dec 31, 2025
Citadel Advisors LLC
23.49K
0.03%
+7.08K
+43.17%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
10.70K
0.01%
+500.00
+4.90%
Dec 31, 2025
XTX Markets LLC
10.63K
0.01%
+10.63K
--
Dec 31, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI